NeOnc's Brain Cancer Efforts Bring Hope as FDA Meeting Approaches
NeOnc Technologies is preparing for an in-person End-of-Phase 1 Type B FDA meeting on NEO212 scheduled for November 17, 2026, to discuss the Phase 2 design, endpoints, and regulatory pathway. Separately, the company reported anecdotal improvement in a child treated with NEO100 in Abu Dhabi and signed a nonbinding MoU with the Department of Health Abu Dhabi covering research collaboration and a possible Phase 1 study in the Emirate. Ali Alabedin of First Abu Dhabi Bank joined NeOnc's board effective October 9, and short interest in NTHI rose roughly 45% between September 15 and September 30.
Key figures
- Fda meeting date
- 2026-11-17
- Fda meeting type
- End-of-Phase 1 Type B (NEO212)
- Short interest sept15
- 522311
- Short interest sept30
- 757739
- Short interest change pct
- approximately 45%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.